Read More

RenovoRx Files New International Patent For Novel Targeted Combination Drug-Delivery Oncology Therapy Platform; Expands IP Coverage For TAMP To Deliver Therapeutic Classes Across DNA/RNA Altering Modalities, Cell Therapy, And Antibody-Based Therapies

RenovoRx Holds a Strong Intellectual Property (IP) Portfolio with 9 Issued Patents for its Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Therapy Platform and Delivery SystemNew Patent Would Expand IP Coverage

RNXT